Indeed, current data assume that MSH2, MLH1, and EpCAM mutation carriers have 13% of cumulative risk incidence of developing gastric tumors at an age of 75 years; however, MSH6 carriers have only 3% of the risk [27]. This evidence concerns the gene MLH1 and gastric neoplasm.